NCT07282847招募中1 期
A Single-Arm, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of AB-1009 in Adult Participants With Late-Onset Pompe Disease (LOPD)
AskBio Inc9 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2026年4月15日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 9
- 主要终点
- Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) during the primary observation period
研究概览
简要总结
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of AB-1009 in adult participants with late-onset Pompe disease (LOPD).
详细描述
This is an open-label study, up to 12 participants will receive a single IV infusion of AB-1009. Participants will be assigned to either cohort 1 (1.0E13 vg/kg) or Cohort 2 (1.5E13 vg/kg) based on enrollment in the study.
Study duration will include a screening period of up to 75 days, primary observation of 52 weeks, and a long-term follow-up period of 4 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be ≥18 to ≤65 years of age at the time of signing the informed consent form.
- •Confirmed GAA enzyme deficiency from any tissue source and/or confirmed biallelic GAA gene mutations.
- •Undergone enzyme replacement treatment (ERT) (either alglucosidase alfa (Lumizyme®), avalglucosidase alfa-ngpt (Nexviazyme®)), or cipaglucosidase alfa (Pombiliti®) for at least 6 months (at least 10 infusions) before signing the initial informed consent form. During the screening process, participants need to remain on their current ERT until close to dosing;
- •FVC in the upright position ≥30% and ≤80% of predicted;
- •Capable of walking at least 100 meters in the 6MWT (use of a cane, quad cane, or standard walker is permitted);
- •Male or female. Contraceptive/barrier use by men and women requirements as per protocol.
- •Capable of giving informed consent.
- •Able to understand and comply with all study procedures.
排除标准
- •Severe cardiomyopathy, defined as left ventricular ejection fraction (LVEF) <40% or New York Heart Association (NYHA) functional class 3 or above;
- •Require invasive mechanical ventilation, or rely on noninvasive ventilation during the day;
- •Intolerance to ERT or investigator-assessed intolerance to ERT, prior experience of serious ERT-related infusion-associated reactions (IARs);
- •Have known intrinsic liver diseases, including hepatitis, HIV-related liver disease, prior diagnosis of portal hypertension, splenomegaly, hepatic encephalopathy, severe fatty liver, cirrhosis or liver fibrosis ≥stage 2, ultrasound-identified liver neoplasms, or laboratory tests suggesting elevated alpha-fetoprotein. Patients with liver function tests including ALT or AST >3× upper limit of normal (ULN) or any total bilirubin above ULN during screening will also be excluded;
- •Prior or ongoing medical condition(s), including any active infection, malignancy within 5 years of screening (except basal or squamous cell skin cancer), physical finding(s), assessment findings, or laboratory abnormality that, in the investigator's opinion, would impact participant's safety and compliance with the study procedures.
- •Have received gene therapy prior to screening;
- •Have received any systemic immunosuppressants (except inhalation or topical use) other than glucocorticoids 30 days prior to screening through completion of screening through completion of screening, and/or known intolerance to immunosuppressants such as glucocorticoids; other concomitant immunosuppression would require sponsor approval.
- •Use of investigational drugs or drugs that could affect this study as evaluated by the investigator within 30 days prior to screening through completion of Week 52 or within 5 half-lives of the investigational drug (whichever is longer);
- •Have received any vaccine within 30 days prior to dosing;
- •Other conditions that make the participant not eligible for the study according to the investigator.
- •Contraindication to MRI, hypersensitivity to contrast dyes, shellfish, or iodine, or implanted spinal rods, cardiac pacemaker, or other implantation that would distort cMRI images.
研究组 & 干预措施
Cohort 1
Experimental
1.0E13 vg/kg
干预措施: AB-1009 (GAA Gene) (Genetic)
Cohort 2
Experimental
1.5E13 vg/kg
干预措施: AB-1009 (GAA Gene) (Genetic)
结局指标
主要结局
Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) during the primary observation period
时间窗: Day 1 (Dosing) through Week 52 (the end of the primary observation period)
Incidence of treatment-emergent adverse events (TEAEs)
时间窗: From Day 1 (Dosing) to Week 52 (the end of the primary observation period)
次要结局
- Change from baseline in GAA activity in muscle biopsy tissue at Week 52(Baseline and Week 52)
- Area under the curve (AUC) of GAA activity in serum(Baseline through Week 52)
- Viral shedding (whole blood, saliva, urine)(Day 1 through Week 24 (or until 3 consecutive data points are at or below the limit of detection))
- AUC of urinary Glc4(Baseline during the primary observation period (through Week 52))
- Change from baseline in muscle biopsy glycogen content at Week 52(Baseline and Week 52)
- Change from baseline in forced vital capacity (FVC) (% predicted) at Week 24 and Week 52(Baseline, Week 24, and Week 52)
- Change from baseline in maximum inspiratory pressure (MIP) at Week 24 and Week 52(Baseline, Week 24, and Week 52)
- Change from baseline in maximum expiratory pressure (MEP) at Week 24 and Week 52(Baseline, Week 24, and Week 52)
- Change from baseline in distance walked in the 6-Minute Walk Test (6MWT) at Week 24 and Week 52(Baseline, Week 24, and Week 52)
- Patient's Global Impression of Change (PGI-C) at Week 24 and Week 52(Week 24 and Week 52)
- Clinical Global Impression of Change (CGI-C) at Week 24 and Week 52(Week 24 and Week 52)
- Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) for physical function changes at Week 24 and Week 52(Baseline, Week 24, and Week 52)
- Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) for fatigue changes at Week 24 and Week 52(Baseline, Week 24, and Week 52)
研究者
研究点 (9)
Loading locations...
相似试验
招募中
2 期
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB ligand) in Combination with Obinutuzumab and in Combination with Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma2022-502616-37-00F. Hoffmann-La Roche AG194
招募中
2 期
A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors2023-507141-28-00Sanofi-Aventis Recherche & Developpement115
招募中
1 期
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsBreast CancerLung CancerNCT07274852Sichuan Baili Pharmaceutical Co., Ltd.22
招募中
1 期
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18
招募中
2 期
(Title in lay language): A trial to learn how safe AZD0516 is and how well it works with and without other cancer treatments in adults with metastatic prostate cancer.Metastatic Prostate Cancer2024-520026-11-00AstraZeneca AB38